Article
Neurosciences
Korbinian Felix Schreyer, Stefan Leucht, Stephan Heres, Werner Steimer
Summary: This study examined the influence of the rs17782313 polymorphism on weight gain induced by second-generation antipsychotics. The results suggest that this polymorphism may have an impact on antipsychotic-induced weight gain, confirming some of the previous findings.
PSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Bea Campforts, Marjan Drukker, Joost Crins, Therese van Amelsvoort, Maarten Bak
Summary: Previous meta-analyses have shown that most antipsychotics are associated with weight gain, but the extent of clinically relevant weight gain or weight loss varies. This study assessed the proportion of patients experiencing clinically relevant weight gain or weight loss when using antipsychotics, and found that almost all antipsychotics were associated with weight gain. Switching antipsychotic medication was also found to be associated with both weight gain and weight loss, with the level of weight gain being higher than weight loss.
Review
Psychology, Multidisciplinary
Yanisa Wannasuphoprasit, Stig Ejdrup Andersen, Maria J. Arranz, Rosa Catalan, Gesche Jurgens, Sanne Maartje Kloosterboer, Henrik Berg Rasmussen, Anjali Bhat, Haritz Irizar, Dora Koller, Renato Polimanti, Baihan Wang, Eirini Zartaloudi, Isabelle Austin-Zimmerman, Elvira Bramon
Summary: The CYP2D6 genetic variation may influence weight gain in individuals taking antipsychotic medications, but further large-scale studies are needed to confirm the association.
FRONTIERS IN PSYCHOLOGY
(2022)
Article
Immunology
Li Li, Eun-Seon Yoo, Xiujuan Li, Steven C. Wyler, Xiameng Chen, Rong Wan, Amanda G. Arnold, Shari G. Birnbaum, Lin Jia, Jong-Woo Sohn, Chen Liu
Summary: Atypical antipsychotics like risperidone and olanzapine can cause drug-induced metabolic syndrome by inhibiting hypothalamic Mc4r neuronal activity, leading to hyperphagia and weight gain.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Psychiatry
Yi Su, Hao Yan, Liangkun Guo, Tianlan Lu, Dai Zhang, Weihua Yue
Summary: The study investigated the association between MTHFR C677T gene polymorphism and antipsychotic-induced weight gain and metabolic abnormalities in patients with schizophrenia. Results showed a significant link between MTHFR C677T and body weight mass index change after 6-week risperidone treatment, indicating a high risk of antipsychotic-induced weight gain and metabolism abnormalities in patients carrying the MTHFR C677 allele.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Multidisciplinary Sciences
Maarten Bak, Marjan Drukker, Shauna Cortenraad, Emma Vandenberk, Sinan Guloksuz
Summary: This meta-analysis found that antipsychotics are associated with body weight gain, regardless of psychiatric diagnosis.
Article
Pharmacology & Pharmacy
Farhana Islam, Xiaoyu Men, Kazunari Yoshida, Clement C. Zai, Daniel J. Mueller
Summary: Pharmacogenetics research has shown that genetic factors influence the efficacy and tolerability of antipsychotic treatment, with the most robust findings related to associations between polymorphisms in CYP2D6 and exposure and response to specific antipsychotics. Product labels and guidelines have provided dosing recommendations based on CYP2D6 metabolizer phenotypes.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Pharmacology & Pharmacy
Vera S. Dobrodeeva, Natalia A. Shnayder, Maxim A. Novitsky, Azat R. Asadullin, Elena E. Vaiman, Marina M. Petrova, Oleg V. Limankin, Nikolay G. Neznanov, Natalia P. Garganeeva, Regina F. Nasyrova
Summary: This study revealed a significant association between the major allele C of SNP rs11100494 of the NPY5R gene and AP-induced weight gain in Russian patients with SSDs, suggesting its predictive role in the development of weight gain. Additionally, first-generation APs were more likely to increase serum transaminase levels, while second-generation APs were more likely to cause weight gain and changes in serum glucose levels.
Article
Health Care Sciences & Services
Gesche Jurgens, Benjamin Skov Kaas-Hansen, Merete Nordentoft, Thomas Werge, Stig Ejdrup Andersen
Summary: This study found an association between genetically predicted CYP2D6 metabolic capacity and antipsychotic-induced weight gain. The results showed significant weight gain in both CYP2D6 poor metabolizers and ultrarapid metabolizers after taking antipsychotic drugs.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Cell Biology
Shangang Zhao, Qian Lin, Wei Xiong, Li Li, Leon Straub, Dinghong Zhang, Rizaldy Zapata, Qingzhang Zhu, Xue-Nan Sun, Zhuzhen Zhang, Jan-Bernd Funcke, Chao Li, Shiuhwei Chen, Yi Zhu, Nisi Jiang, Guannan Li, Ziying Xu, Steven C. Wyler, May-Yun Wang, Juli Bai, Xianlin Han, Christine M. Kusminski, Ningyan Zhang, Zhiqiang An, Joel K. Elmquist, Olivia Osborn, Chen Liu, Philipp E. Scherer
Summary: Antipsychotic drugs can cause weight gain and diabetes, and hyperleptinemia plays a key role. Suppression of leptin rise can reduce the adverse effects of these drugs.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Haodong Liu, Xiaojing Li, Penghui Li, Rihan Hai, Jiacheng Li, Qi Fan, Xing Wang, Yujie Chen, Xiaojuan Cao, Xiaoyu Zhang, Ruifeng Gao, Kun Wang, Chenguang Du
Summary: By conducting experiments on mice, it was discovered that VGlut2 neurons in the locus coeruleus play a significant role in weight regulation, while MC4R neurons in the paraventricular nucleus also contribute to weight management. Furthermore, LCVGlut2 neurons exhibit wide-ranging projections, receiving excitatory inputs from multiple brain nuclei. These findings have important implications for the treatment of obesity.
Article
Psychology, Developmental
Hua Chen, Ning Lyu, Wenyaw Chan, Austin De La Cruz, Chadi Calarge
Summary: This study examines the utilization and predictors of adjuvant metformin among pediatric recipients of second-generation antipsychotics. The findings suggest that the utilization of adjuvant metformin is uncommon among pediatric SGA recipients, and early introduction of the medication among nonobese children is rare.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)
Review
Endocrinology & Metabolism
Helene Speyer, Casper Westergaard, Nikolai Albert, Mette Karlsen, Anne Emilie Sturup, Merete Nordentoft, Jesper Krogh
Summary: The study found that reducing dosage, discontinuing medication, or switching to a partial agonist can lead to a small but significant weight loss of around 1.5 kg. The overall weight change from pre to post intervention was a reduction of 1.13 kg.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Sophie Courbage, Christine Poitou, Johanne Le Beyec-Le Bihan, Alexandra Karsenty, Julie Lemale, Veronique Pelloux, Jean-Marc Lacorte, Jean-Claude Carel, Nathalie Lecomte, Caroline Storey, Gianpaolo De Filippo, Muriel Coupaye, Jean-Michel Oppert, Patrick Tounian, Karine Clement, Beatrice Dubern
Summary: This study found that heterozygous variants in LEP, LEPR, POMC, and PCSK1 are common in severe obesity and sometimes exhibit a phenotype similar to homozygotes. These data suggest the importance of systematically searching for variants in severe early-onset obesity and discussing targeted therapy.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Psychiatry
Kenn Lee, Seri Abraham, Robert Cleaver
Summary: This study evaluated the efficacy of licensed weight loss medications (WLMs) for treating antipsychotic-induced weight gain (AIWG) and obesity in schizophrenia and psychosis. The findings showed that liraglutide had the strongest evidence compared to other licensed WLMs in improving weight, BMI, waist circumference, HbA1c, cholesterol, and LDL readings. This evidence supports the use of liraglutide in treating AIWG and OSP.
GENERAL HOSPITAL PSYCHIATRY
(2022)
Article
Neurosciences
Prabhjot Dhami, Lena C. Quilty, Benjamin Schwartzmann, Rudolf Uher, Timothy A. Allen, Stefan Kloiber, Raymond W. Lam, Glenda MacQueen, Benicio N. Frey, Roumen Milev, Daniel J. Mueller, Stephen C. Strother, Pierre Blier, Claudio N. Soares, Sagar V. Parikh, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Faranak Farzan
Summary: The neurobiological correlates of response inhibition can predict the response of patients with major depressive disorder (MDD) to pharmacological and cognitive behavioral therapy treatment. The integrity of response inhibition may be crucial for the success of treatment for MDD. Electrophysiological correlates of response inhibition may serve as a general prognostic marker for treatment response in MDD.
BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING
(2023)
Review
Clinical Neurology
Jose M. M. Rubio, Daniel Guinart, John M. M. Kane, Christoph U. U. Correll
Summary: This systematic review and meta-analysis examined the management strategies for schizophrenia patients with early non-response to antipsychotic treatment. The study found that there is limited evidence and uncertainty regarding the best treatment strategies for early non-response.
Article
Genetics & Heredity
Chia-Yen Chen, Ruoyu Tian, Tian Ge, Max Lam, Gabriela Sanchez-Andrade, Tarjinder Singh, Lea Urpa, Jimmy Z. Liu, Mark Sanderson, Christine Rowley, Holly Ironfield, Terry Fang, Mark Daly, Aarno Palotie, Ellen A. Tsai, Hailiang Huang, Matthew E. Hurles, Sebastian S. Gerety, Todd Lencz, Heiko Runz
Summary: A large-scale exome study identifies eight genes associated with adult cognitive function through rare coding variants with large effects. The rare genetic architecture for cognitive function partially overlaps with that of neurodevelopmental disorders. The study reveals the relevance of rare coding variants and high-impact monogenic contributions to the distribution of cognitive function in the adult population.
Review
Behavioral Sciences
Samuele Cortese, Katherine McGinn, Mikkel Hojlund, Alan Apter, Celso Arango, Immaculada Baeza, Tobias Banaschewski, Jan Buitelaar, Josefina Castro-Fornieles, David Coghill, David Cohen, Edna Grunblatt, Pieter J. Hoekstra, Anthony James, Pia Jeppesen, Peter Nagy, Anne Katrine Pagsberg, Mara Parellada, Antonio M. Persico, Diane Purper-Ouakil, Veit Roessner, Paramala Santosh, Emily Simonoff, Dejan Stevanovic, Argyris Stringaris, Benedetto Vitiello, Susann Walitza, Abraham Weizman, Tamar Wohlfarth, Ian C. K. Wong, Gil Zalsman, Alessandro Zuddas, Carmen Moreno, Marco Solmi, Christoph U. Correll
Summary: In order to identify potential novel medications for child and adolescent mental health problems, we conducted a systematic search on clinical trial databases from 2010 to 2022. We included phase 2 or 3 randomized controlled trials (RCTs) of medications without regulatory approval in the US, Europe or Asia, and also RCTs of dietary interventions/probiotics. We found 234 ongoing or completed RCTs, with varying results on primary outcomes.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2023)
Article
Psychology, Clinical
Pavol Mikolas, Michael Marxen, Philipp Riedel, Kyra Broeckel, Julia Martini, Fabian Huth, Christina Berndt, Christoph Vogelbacher, Andreas Jansen, Tilo Kircher, Irina Falkenberg, Martin Lambert, Vivien Kraft, Gregor Leicht, Christoph Mulert, Andreas J. Fallgatter, Thomas Ethofer, Anne Rau, Karolina Leopold, Andreas Bechdolf, Andreas Reif, Silke Matura, Felix Bermpohl, Jana Fiebig, Thomas Stamm, Christoph U. Correll, Georg Juckel, Vera Flasbeck, Philipp Ritter, Michael Bauer, Andrea Pfennig
Summary: Machine learning using structural magnetic resonance imaging can aid in early recognition of bipolar disorder risk and reduce disease burden.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Clinical Neurology
Martin Koster Rimvall, Ditte Vassard, Sabrina Mai Nielsen, Rasmus Trap Wolf, Kerstin Jessica Plessen, Niels Bilenberg, Per Hove Thomsen, Mikael Thastum, Simon-Peter Neumer, Louise Berg Puggaard, Mette Maria Agner Pedersen, Anne Katrine Pagsberg, Wendy K. Silverman, Christoph U. Correll, Robin Christensen, Pia Jeppesen
Summary: The study found that Mind My Mind (MMM) cognitive behavioral therapy is effective in treating common emotional and behavioral mental health problems in youth, but not all individuals respond satisfactorily to treatment. The analysis revealed that youths with any mental disorder at baseline, comorbidity, and longer duration of untreated mental health problems showed superior treatment benefits. This highlights the importance of community-based programs like MMM for youth with substantial mental health problems.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Article
Psychiatry
Ching-Fang Sun, Christoph U. Correll, Robert L. Trestman, Yezhe Lin, Hui Xie, Maria Stack Hankey, Raymond Paglinawan Uymatiao, Riya T. Patel, Vemmy L. Metsutnan, Erin Corinne McDaid, Atreyi Saha, Chin Kuo, Paula Lewis, Shyam H. Bhatt, Lauren Elizabeth Lipphard, Anita S. Kablinger
Summary: This study examined the barriers to care in the general psychiatry outpatient appointments in the US, comparing different insurance types, states, and urbanization levels. The results showed low accessibility and long wait times for psychiatric care, with a potential solution being to transition to telepsychiatry for rural areas.
GENERAL HOSPITAL PSYCHIATRY
(2023)
Article
Neurosciences
Hengyi Cao, Anita D. Barber, Jose M. Rubio, Miklos Argyelan, Juan A. Gallego, Todd Lencz, Anil K. Malhotra
Summary: This study investigates the influence of phase encoding direction (PED) on the test-retest reliability of functional connectome in fMRI studies. The results show that PA scans have significantly higher intraclass correlation coefficients (ICCs) for global, nodal, and edge connectivity compared to AP scans. Better temporal signal-to-noise ratio (tSNR) reliability is also observed in PA scans. Averaging the connectivity outcome from both PEDs can increase ICCs, especially at the nodal and edge levels.
Article
Psychiatry
Daniel Schoettle, Klaus Wiedemann, Christoph U. Correll, Wolfgang Janetzky, Michael Friede, Holger Jahn, Andreas Brieden
SCHIZOPHRENIA RESEARCH
(2023)
Review
Psychology, Clinical
Bettina Frank, Sabine Arnold, Charlotte Jaite, Christoph U. Correll
Summary: This study found that the use of antipsychotic medication in the treatment of anorexia nervosa in youth did not significantly improve weight restoration compared to those not treated with antipsychotics. The weight and treatment duration of the youth who received antipsychotic treatment were also worse compared to those who did not receive such treatment.
JOURNAL OF EATING DISORDERS
(2023)
Article
Pediatrics
Laura M. Watrin-Avino, Franziska J. Forbes, Martin C. Buchwald, Katja Dittrich, Christoph U. Correll, Felix Bermpohl, Katja Boedeker
Summary: This study aimed to investigate the impairments in affect recognition, theory of mind (ToM), and empathy in preschoolers with externalizing behavior problems (EBPs). The results showed that these children had significant impairments in cognitive ToM, attention to others' feelings, and prosocial action. This highlights the importance of promoting social cognitive development in early childhood.
Article
Psychology, Clinical
Martin Zack, Daniela Lobo, Candice Biback, Tim Fang, Kelly Smart, Daniel Tatone, Aditi Kalia, Daniel Digiacomo, James L. Kennedy
Summary: This study aimed to investigate the effects of gambling-specific priming manipulations and the pharmacological basis on risk-taking in a Game of Dice Task (GDT). The results showed that both gambling and AMPH increased risk-taking, with a stronger effect observed in individuals with gambling disorder. The outcomes varied with pre-treatment, and cognitive inflexibility and symptom severity moderated the effects.
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY
(2023)
Article
Psychiatry
Christoph U. U. Correll, Carmela Benson, Bruno Emond, Charmi Patel, Marie-Helene Lafeuille, Dee Lin, Laura Morrison, Isabelle Ghelerter, Patrick Lefebvre, Panagiotis Mavros
Summary: This retrospective study evaluated the benefit of different long-acting injectable (LAI) initiation strategies based on timing of behavioral and clinical events among Medicaid beneficiaries with schizophrenia. The study found that initiating LAIs prior to nonadherence to oral antipsychotics (OAPs) or occurrence of schizophrenia-related inpatient/ER visits was associated with fewer all-cause inpatient days and ER visits. Therefore, the LAI initiation strategy plays an important role in improving clinical outcomes for patients with schizophrenia.
Article
Clinical Neurology
Robert Litman, Dieter Naber, Lourdes Anta, Javier Martinez, Yuriy Filts, Christoph U. Correll
Summary: This study aimed to investigate the impact of Risperidone ISM on social functioning and health-related quality of life in patients with schizophrenia. The results showed that Risperidone ISM significantly improved social functioning and HR-QoL, and the therapeutic effects were rapid and sustained.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2023)
Review
Biochemistry & Molecular Biology
Michele Fornaro, Claudio Caiazza, Niccolo Solini, Michele De Prisco, Martina Billeci, Martina Vannini, Risa Shorr, Stefano Caiolo, Marialaura Lussignoli, Dan Siskind, Giorgio Pigato, Annarita Barone, Fabio Sambataro, Andrea de Bartolomeis, Christoph U. Correll, Marco Solmi
Summary: This study conducted a network meta-analysis on antipsychotic-induced sialorrhea. The results showed that dopamine receptor antagonists, metoclopramide, and sulpiride were effective in treating sialorrhea, while antihistamines and atropine showed no significant effect on nocturnal sialorrhea. This study provides some guidance for the treatment of antipsychotic-related sialorrhea.
MOLECULAR PSYCHIATRY
(2023)